Penicillamine in rheumatoid disease: a long-term study

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Medicine

Background:

• Rheumatoid disease management presents challenges.
• Penicillamine is a treatment option for rheumatoid disease.
• Understanding penicillamine's efficacy and adverse effects is crucial.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of penicillamine in rheumatoid disease patients.
• To identify factors influencing treatment discontinuation due to adverse reactions.
• To establish optimal dosing and monitoring strategies for penicillamine therapy.

Main Methods:

• Prospective study of 85 patients with rheumatoid disease treated with penicillamine.
• Analysis of treatment completion rates, reasons for withdrawal, and adverse reactions.
• Evaluation of treatment outcomes based on drug tolerance and dose adjustments.

Main Results:

• 69 out of 85 patients completed over one year of penicillamine treatment.
• Adverse reactions were the primary reason for discontinuation in 16 patients.
• Lower maintenance doses of penicillamine significantly reduced the incidence of adverse reactions.
• Patients tolerating the drug experienced good treatment outcomes.

Conclusions:

• Penicillamine can be effective in treating rheumatoid disease.
• Gradual dose introduction and use of the lowest effective maintenance dose are key to minimizing side effects.
• Regular monitoring of urine protein and blood counts (platelets, white cells) is essential for patient safety during penicillamine therapy.